Back To Search Results

Bacterial DNA Mutations

Editor: Steven J. Warrington Updated: 4/10/2023 2:58:48 PM


Genomes of bacteria exist on a single double-stranded circular DNA molecule that contains approximately 4000 kb of DNA and are regulated by operons. A mutation is a change in the nucleotide sequence and can create new cellular functionalities or lead to the dysfunction of others. Mutations can occur spontaneously or be caused by exposure to mutation-inducing agents.[1]


Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care


While the majority of bacterial genes exist on one circular chromosome, there are other genetic elements within the bacterial genome. Elements like plasmids, transposons, integrons, or gene cassettes are shorter sequences that mainly contribute to recombination events. Bacterial DNA replication and transcription co-occur and utilize the same template DNA. Replication forks proceed bi-directionally with a single origin of replication, OriC.

Bacterial genes with similar functions often share one promoter (RNA polymerase binding site) and are transcribed simultaneously; this system is called an operon. Typical operons consist of several structural genes that code for the enzymes required for the pathway. Regulation occurs through transcription factors binding to a short sequence of DNA between the promoter region and the structural genes called an operator.[2]

A mutation is a change in the nucleotide sequence of a short region of a genome, and phenotypic results may vary on the severity and location of the mutation. Mutations can result from errors during DNA replication or induced by exposure to mutagens (like chemicals and radiation). Spontaneous mutations occur at a rate of 1 in 10^5 to 10^8 and contribute to random population variation.[3] Since bacteria are haploid for the majority of their genes and have short generation turnover, phenotypic variation due to point mutations can occur relatively quickly.

Results of mutations can produce changes in structural or colony characteristics or loss in sensitivity to antibiotics. Some potential consequences of mutations are as follows:

  • Auxotrophs: have a mutation that leaves an essential nutrient process dysfunctional.
  • Resistant mutants: can withstand the stress of exposure to inhibitory molecules or antibiotics secondary to acquired mutation.
  • Regulatory mutants have disruptions on regulatory sequences like promotor regions.
  • Constitutive mutants: continuously express genes that usually switch on and off as in operons.

Spontaneous Mutations

Spontaneous mutations occur without mutation induction and are the result of errors during DNA replication. When DNA Pol III synthesizes a new strand of DNA, occasionally, a nucleotide will be mispaired, added, or omitted.[4] Thus, a point mutation will occur. For example, when nucleotides are mispaired, it will appear that one nucleotide substitutes for another leading to one mutated granddaughter DNA strand. Two separate malfunctions must happen in the bacteria's DNA replication machinery for this to occur:[5]

  • DNA pol III pairs an incorrect complementary nucleotide base onto the parent strand in the replication fork
  • The chemical activity of the mispairing is not enough to slow the polymerase portion of DNA polymerase so that the exonuclease can remove the mispair
  • Studies with Escherichia coli show that spontaneous mutations occur 20 times more often on the lagging strand than the leading strand.[6]

DNA bases can exist in many different forms, referred to as tautomers. Nucleotide bases dominantly exist in the keto (C-O) and amino (C-NH2) forms, while the imino (C≡NH) and enol (C-OH) occur rarely. Tautomerization, during DNA replication, will alter nucleotide base pair formation. For example, assume that thymine undergoes keto-enol tautomerization during replication. This enol species will preferentially bind to guanine during the first replication cycle. Due to the semiconservative nature of DNA replication, at the end of the 2nd round of replication, there will be (3) A-T base pairs and (1) G-C in the locus of mutation.[7]

 The mechanism is as follows:

  • T – A --> Tautomerization --> T' – A --> replication 1 --> T' – G and A –T
  • T – G --> Replication 2 --> T – A and G – C

(enol form of thymine indicated as T')[8]

Errors in DNA replication can result in the addition of erroneous nucleotides or the deletion of template nucleotides. For example, loci with a high number of short repeat nucleotides are prone to polymerase slippage. During replication, the DNA Pol III temporarily dissociates from the template strand. The DNA polymerase may relocate a few repeats upstream or downstream of its original locus along with its newly synthesized strand.  Slip strand mispairing can result in addition/deletion mutations because some nucleotides are replicated twice while others do not replicate. If the repeats are not in a multiple of three, the mutation can result in a frameshift (A shift in the coding sequence downstream of the mutation). These mutations lead to loss of normal protein functionality. Slip-strand mispairings can increase the variation in short tandem repeats (STRs) in a bacterial population and are useful in genetic testing. When an addition or deletion occurs, the potential genomic outcomes are as follows:[9]

  • Silent mutation: The mutation changes the original codon into another codon that codes for the same amino acid
  • Missense mutation: When a mutation in the sequence causes a codon to code for a different amino acid
  • Nonsense mutation: A mutant stop codon replaces a wild-type codon, terminating translation resulting in a shortened protein.

The mutation's phenotypical severity depends on the structure of the substituted amino acid's effect on the final protein product. More specifically, non-synonymous amino acid substitutions produce dramatic changes in protein structures because of the chemical dis-similarities of the mutated strand amino acid. However, there are inherent protections against these types of mutations. The redundancy of codon translation mechanisms and the occurrence of non-coding regions result in few mutations expressing phenotypically.[10]

Mutation Induction

Mutagens may be of physical, chemical, or biological origin. Mostly they act on the DNA directly, causing damage, which may result in errors during replication. Although severely damaged DNA can prevent replication and cause cell death. SOS is an example of cellular response to DNA damage that results in cell cycle arrest and induction of mutagenesis. Rec A induces SOS response by recognizing single-stranded DNA and activating mutagenic DNA polymerases (II, IV, and V).[11]

The following are several classes of mutagens and their subsequent effects  : 

Physical Mutagens

Examples of physical mutagens include radiation or UV exposure. UV radiation damages DNA by creating covalent linkages between adjacent pyrimidine bases. This pyrimidine dimer cannot fit well in the double helix structure of DNA, thus inhibiting replication and translation. However, dimer formation usually results in a deletion mutation. Other types of radiation can have a variety of effects (Depending on intensity and wavelength), but mostly insertions/deletions occur. Purine dimers rarely occur.[12]

Chemical Mutagens

Chemical mutagens are agents that either directly or indirectly induce mutations.[13] A chemical mutagen can either replace a base in DNA, alter a base's composition and pairing behavior, or damage the base so that it can no longer pair. These include DNA reactive chemicals such as those listed below:

Base Analogs

Structurally similar enough to nucleotides in that they can incorporate into DNA. For example, 5-bromouracil, an analog of thymine, acts as a substrate during DNA replication and causes point mutations. This mispairing occurs because the base analog forms a tautomer and pairs with guanine instead of adenine.[14]

Reactive Oxygen Species

Hydroxyl radicals attack guanine, thereby producing 8-hydroxy-deoxyguanosine (8-OhdG), which mispairs with adenine instead of cytosine, which results in a (G -> T) transversion during replication.[15]

Deaminating Agents

These agents remove amino groups on nucleotide bases. Deaminating agents produce an adenine species that pairs with cytosine and a cytosine species (uracil) that pairs with adenine. Deamination of guanine results in xanthine, which inhibits replication, thereby not creating a mutation.[15]

Flat Aromatic Compounds

Acridines like ethidium bromide can intercalate with adjacent pyrimidine base pairs. This interaction slightly unwinds the helix and increases the distance between adjacent base pairs. This intercalation disrupts the reading frame during translation and can cause insertions or deletions.[16]

Alkylating Agents

Agents like ethyl methanesulfonate and dimethyl nitrosoguanidine alter the nucleotide base by adding alkyl groups. The nature and position of the alkylation can vary but usually leads to point mutations through base mispairing. However, alkylation can cause crosslink formation, which inhibits replication. 

Biological Mutagens

Biological agents of mutation are sources of DNA from elements like transposons and viruses. Transposons are sequences of DNA that can relocate and replicate autonomously. Insertion of a transposon into a DNA sequence can disrupt gene functionality. Transposition is not technically a type of recombination but is mechanistically similar. Transposons often pair with short regions of nucleotide repeats on either side of the transposition sequence.[1] There are three types of transposons:

  • Replicative transposons keep the original locus and translocate a copy 
  • Conservative transposons occur when the original transposon translocates 
  • Retrotransposons transpose via RNA intermediates 

Clinical Significance

Antibiotic Resistance

Antibiotics work through a variety of mechanisms:[17]

  1. DNA synthesis inhibitors
  2. Protein synthesis inhibitors
  3. Cell wall synthesis inhibitors
  4. RNA synthesis inhibitors
  5. Mycolic acid synthesis inhibitors
  6. Folic acid synthesis inhibitors

When an antibiotic loses the capacity to kill or control bacterial growth, antibiotic resistance occurs. This can occur in two ways:

  1. Through genetic mutation
  2. Acquisition of resistance from other bacteria

These circumstances exacerbate under selective pressure (i.e., the use of antibiotics). Antibiotic resistance can spread both vertically and horizontally through a population. Horizontal transfer is considered the primary mediator of antibiotic resistance. The following are non-comprehensive examples of how two of the classes of antibiotics mentioned above encounter resistance mutations.

DNA Synthesis Inhibitor

In gram-negative bacteria, such as Helicobacter pylori, mutation resistance occurs relatively quickly to fluoroquinolones and thereby poses clinical issues for these therapies. Levofloxacin, moxifloxacin, and ciprofloxacin, examples of fluoroquinolones, inhibit DNA synthesis by targeting two homologous enzymes (DNA topoisomerase II and IV).[18] These enzymes are necessary for the supercoiling of bacterial DNA.  

Gram-negative bacterial resistance to fluoroquinolones includes the accumulation of substitution mutations in the coding regions for particular subunits of DNA topoisomerase II. Resistance can be enhanced further by efflux pump modification.[19] Ciprofloxacin targets only the parC subunit while other quinolones target one or more of these subunits.[20] For example, garenoxacin targets both DNA topoisomerases II and IV thus is less prone to resistance. Resistance to Garenoxacin requires both proteins to have resistance mutations.[21]

Combination therapy for Helicobacter pylori typically includes clarithromycin (protein synthesis inhibitor), metronidazole (DNA synthesis inhibitor), amoxicillin (Cell wall synthesis inhibitor), or tetracycline (protein synthesis inhibitor), and a proton pump inhibitor.[22][23][24]

Protein Synthesis Inhibitor

Linezolid prevents protein synthesis and is active against resistant Gram-positives.[25] Linezolid inhibits the formation of the 70S ribosomal initiation complex through binding to the 23S portion of the 50S subunit.[26] Infrequent resistance found in strains of S. aureus, and coagulase-negative staphylococci has mutations in the central loop of the domain V region of the 23S rRNA gene. More specifically, clinical isolates had a substitution of Thymine for Guanine at the 2576 position.[27][28]

Intrinsically, resistant bacteria have a characteristic resistance within all members of a species or genus. Such resistance may arise because:

  1. Glycopeptides are too large to penetrate the outer membrane (gram-positive bacteria)
  2. Antibiotics lack affinity for the target (penicillin-binding proteins of gram-positive bacteria)
  3. Presence of efflux pumps expression (multi-drug efflux pumps of Pseudomonas aeruginosa)[29]
  4. Other chromosomal resistance mechanisms 

Antibiotic resistance mechanisms can also occur by incorporating resistance genes into plasmids, transposons, and integrons. These genes spread through horizontal transfer by conjugation, transformation, or transduction mechanisms. However, the mutation is essential for the evolution or assortment of these genes.

Enhancing Healthcare Team Outcomes

Infectious disease specialists, both clinicians and pharmacists, need to understand the mechanisms by which bacteria can undergo DNA mutations, as these mutations can confer resistance against agents that were previously effective. By understanding the mechanism and careful tracking through antibiograms, antimicrobial therapy can be targeted for the greatest effectiveness without contributing to mutations that will create "superbugs." This will result in better antibiotic therapy resulting in improved patient outcomes with fewer adverse events and the need for ever stronger broad-spectrum drugs.



Woodford N, Ellington MJ. The emergence of antibiotic resistance by mutation. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2007 Jan:13(1):5-18     [PubMed PMID: 17184282]


Andersson DI, Slechta ES, Roth JR. Evidence that gene amplification underlies adaptive mutability of the bacterial lac operon. Science (New York, N.Y.). 1998 Nov 6:282(5391):1133-5     [PubMed PMID: 9804552]


Torii N, Nozaki T, Masutani M, Nakagama H, Sugiyama T, Saito D, Asaka M, Sugimura T, Miki K. Spontaneous mutations in the Helicobacter pylori rpsL gene. Mutation research. 2003 Mar 3:535(2):141-5     [PubMed PMID: 12581531]


Goodman MF. Coping with replication 'train wrecks' in Escherichia coli using Pol V, Pol II and RecA proteins. Trends in biochemical sciences. 2000 Apr:25(4):189-95     [PubMed PMID: 10754553]


Kreuzer KN. DNA damage responses in prokaryotes: regulating gene expression, modulating growth patterns, and manipulating replication forks. Cold Spring Harbor perspectives in biology. 2013 Nov 1:5(11):a012674. doi: 10.1101/cshperspect.a012674. Epub 2013 Nov 1     [PubMed PMID: 24097899]

Level 3 (low-level) evidence


Fijalkowska IJ, Schaaper RM, Jonczyk P. DNA replication fidelity in Escherichia coli: a multi-DNA polymerase affair. FEMS microbiology reviews. 2012 Nov:36(6):1105-21. doi: 10.1111/j.1574-6976.2012.00338.x. Epub 2012 Apr 5     [PubMed PMID: 22404288]


Karalkar NB, Khare K, Molt R, Benner SA. Tautomeric equilibria of isoguanine and related purine analogs. Nucleosides, nucleotides & nucleic acids. 2017 Apr 3:36(4):256-274. doi: 10.1080/15257770.2016.1268694. Epub 2017 Mar 23     [PubMed PMID: 28332916]


Khuu P, Ho PS. A rare nucleotide base tautomer in the structure of an asymmetric DNA junction. Biochemistry. 2009 Aug 25:48(33):7824-32. doi: 10.1021/bi900829b. Epub     [PubMed PMID: 19580331]


Fan H, Chu JY. A brief review of short tandem repeat mutation. Genomics, proteomics & bioinformatics. 2007 Feb:5(1):7-14     [PubMed PMID: 17572359]


Dailidiene D, Bertoli MT, Miciuleviciene J, Mukhopadhyay AK, Dailide G, Pascasio MA, Kupcinskas L, Berg DE. Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrobial agents and chemotherapy. 2002 Dec:46(12):3940-6     [PubMed PMID: 12435699]


Selwood T, Larsen BJ, Mo CY, Culyba MJ, Hostetler ZM, Kohli RM, Reitz AB, Baugh SDP. Advancement of the 5-Amino-1-(Carbamoylmethyl)-1H-1,2,3-Triazole-4-Carboxamide Scaffold to Disarm the Bacterial SOS Response. Frontiers in microbiology. 2018:9():2961. doi: 10.3389/fmicb.2018.02961. Epub 2018 Dec 18     [PubMed PMID: 30619111]


Francino MP, Ochman H. Strand asymmetries in DNA evolution. Trends in genetics : TIG. 1997 Jun:13(6):240-5     [PubMed PMID: 9196330]


Nicolette J, Dakoulas E, Pant K, Crosby M, Kondratiuk A, Murray J, Sonders P, Kulkarni R, Jayakumar G, Mathur M, Patel A, Vicente R, Datta K, Kolaja K. A comparison of 24 chemicals in the six-well bacterial reverse mutation assay to the standard 100-mm Petri plate bacterial reverse mutation assay in two laboratories. Regulatory toxicology and pharmacology : RTP. 2018 Dec:100():134-160. doi: 10.1016/j.yrtph.2018.10.005. Epub 2018 Oct 26     [PubMed PMID: 30401633]


Janion C, Bebenek K, Plewako S. Are Escherichia coli dam- as compared to dam+ hypermutable by base analogs? Acta biochimica Polonica. 1987:34(2):183-93     [PubMed PMID: 3314290]


Cadet J, Wagner JR. Oxidatively generated base damage to cellular DNA by hydroxyl radical and one-electron oxidants: similarities and differences. Archives of biochemistry and biophysics. 2014 Sep 1:557():47-54. doi: 10.1016/ Epub 2014 May 10     [PubMed PMID: 24820329]


Martins M, McCusker MP, Viveiros M, Couto I, Fanning S, Pagès JM, Amaral L. A Simple Method for Assessment of MDR Bacteria for Over-Expressed Efflux Pumps. The open microbiology journal. 2013:7():72-82. doi: 10.2174/1874285801307010072. Epub 2013 Mar 22     [PubMed PMID: 23589748]


Everett MJ, Jin YF, Ricci V, Piddock LJ. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrobial agents and chemotherapy. 1996 Oct:40(10):2380-6     [PubMed PMID: 8891148]

Level 3 (low-level) evidence


Hawkey PM. Mechanisms of quinolone action and microbial response. The Journal of antimicrobial chemotherapy. 2003 May:51 Suppl 1():29-35     [PubMed PMID: 12702701]


De Kievit TR, Parkins MD, Gillis RJ, Srikumar R, Ceri H, Poole K, Iglewski BH, Storey DG. Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrobial agents and chemotherapy. 2001 Jun:45(6):1761-70     [PubMed PMID: 11353623]


Pereyre S, Renaudin H, Bébéar C, Bébéar CM. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas. Antimicrobial agents and chemotherapy. 2004 Aug:48(8):3165-8     [PubMed PMID: 15273141]


Ince D, Zhang X, Silver LC, Hooper DC. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrobial agents and chemotherapy. 2002 Nov:46(11):3370-80     [PubMed PMID: 12384338]


Okamoto T, Yoshiyama H, Nakazawa T, Park ID, Chang MW, Yanai H, Okita K, Shirai M. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. The Journal of antimicrobial chemotherapy. 2002 Dec:50(6):849-56     [PubMed PMID: 12461003]


Rayner C, Munckhof WJ. Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus. Internal medicine journal. 2005 Dec:35 Suppl 2():S3-16     [PubMed PMID: 16271060]


Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. Journal of molecular microbiology and biotechnology. 2001 Apr:3(2):255-64     [PubMed PMID: 11321581]


Woodford N. Novel agents for the treatment of resistant Gram-positive infections. Expert opinion on investigational drugs. 2003 Feb:12(2):117-37     [PubMed PMID: 12556209]

Level 3 (low-level) evidence


Broder KW, Moise PA, Schultz RO, Forrest A, Schentag JJ. Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis. Annals of plastic surgery. 2004 Apr:52(4):385-90     [PubMed PMID: 15084884]


Wolter N, Smith AM, Farrell DJ, Schaffner W, Moore M, Whitney CG, Jorgensen JH, Klugman KP. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrobial agents and chemotherapy. 2005 Aug:49(8):3554-7     [PubMed PMID: 16048983]


Hong T, Li X, Wang J, Sloan C, Cicogna C. Sequential linezolid-resistant Staphylococcus epidermidis isolates with G2576T mutation. Journal of clinical microbiology. 2007 Oct:45(10):3277-80     [PubMed PMID: 17670931]

Level 3 (low-level) evidence


Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. The Journal of antimicrobial chemotherapy. 2003 Jan:51(1):9-11     [PubMed PMID: 12493781]

Level 3 (low-level) evidence